XPENG Presents Next-Gen Technology Architecture – SEPA2.0
17.4.2023 04:18:00 EEST | Business Wire | Press release
XPeng Inc. (“XPENG” or the “Company,” NYSE: XPEV and HKEX: 9868), a leading Chinese smart electric vehicle (“Smart EV”) company, today unveiled its next-generation end-to-end integrated technology architecture SEPA2.0, which sets the foundation for future production models.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230416005077/en/
XPENG SEPA2.0 (Photo: Business Wire)
SEPA2.0 (Smart Electric Platform Architecture) brings a series of more advanced architectural solutions, from XPENG’s in-house development autonomous driving software to vehicle engineering. It will shorten future models’ R&D cycle by 20%, significantly optimizing R&D efficiency. 80% of architectural components will be compatible with new models, enabling XPENG to meet diverse customer needs at optimized costs.
SEPA2.0 is adaptable and flexible with multiple vehicle platforms for wheelbases between 1,800mm and 3,200mm and scalable to support a variety of vehicle types, including sedan, coupe, hatchback, wagon, SUV, MPV and pickup truck. On April 18, the first new production model built on SEPA2.0, XPENG G6 Ultra Smart Coupe SUV, will debut at Auto Shanghai 2023.
“We envision that this evolutionary intelligent architecture will lead smart EV technology development for the next three years. It will make rapid advancements in technology available for our customers as standard, with faster software upgrades, stunning cost savings and elevated product experience,” said He Xiaopeng, Chairman and CEO of XPENG. “Ultimately, SEPA2.0 will architecturally empower us in our ongoing quest to redefine mobility experience with compelling value, superb comfort and rich infotainment.”
English replay of XPENG SEPA2.0 Press Briefing: https://www.youtube.com/watch?v=ed99lGrtxn0
XPENG SEPA2.0 visual library: https://drive.google.com/drive/folders/1q1ZKsHv2V2vVoEUIXXWQ5pGrBbRBIlNA
XPENG SEPA2.0 smart manufacturing video: https://drive.google.com/drive/folders/1dF5sH5UdcP-ggyR-sVWFdwtFZTpDafhO
Intelligent Architecture to Accelerate Smart Technology Inclusion
- XNGP Advanced Driver Assistance System (ADAS): XPENG’s in-house full-scenario ADAS solution is the ultimate form of driver assistance and will come as standard on all future XPENG models for the Chinese market. With SEPA2.0 architecture, XNGP’s overall R&D efficiency will increase by 30%, while ADAS software model adaptation costs will reduce by 70%. Backed by China’s largest and only operational autonomous driving supercomputing center, closed-loop data feedback and self-evolving AI system, XNGP will consistently evolve and upgrade its driving assistance skills. It targets takeover frequency less than once per 1000 km in highway scenarios in 2023 and takeover frequency less than once per 100 km in urban scenarios by 2025.
- Xmart OS In-car Operating System: Xmart OS leverages a multi-sensor software and hardware platform to augment and transform control and driver-vehicle interaction. Powered by AI, supercomputers and foundation models, Xmart OS can make intelligent decisions to optimize control of cabin functions. The SEPA2.0-based R&D platform lowers Xmart OS software adaptation costs by 85%, shortens voice software R&D cycle by 50% and reduces cost of voice assistant service by 50%, making the industry’s top smart cabin services available to every XPENG owner, while revolutionizing cockpit instrumentation and road perception.
- X-EEA Electrical and Electronic Architecture: Consisting of a data technology platform, a whole-car software platform and a hardware architecture platform, X-EEA underpins XPENG’s technology foundation with high performance, superior safety and cloud application integration. It optimizes overall vehicle R&D costs by 50%, shortens software iteration cycles by 30% and increases OTA update speed by 300%.
Architecture-based Solutions to Boost Charging Efficiency
- 800 Volt High Voltage Silicon Carbide (SiC) Platform: XPENG’s industry leading superfast charging solution enables 800V high voltage charging, increasing battery charging speed by 50% over the previous generation. With a standard 3C cell configuration, the battery can add 130 kilometers of range with a five-minute charge, and can charge even faster at XPENG’s S4 480kW superfast charging facilities, adding 200 km of range with a five-minute charge. When charging via third-party charging piles, it can generate up to 180kW of charging power.
- XPower 800 Volt High Voltage Oil-cooled Flat-wire SiC Integrated Electric Drive System: Full-stack and in-house developed, XPower increases the maximum electric drive efficiency to 97.5% and the overall electric drive efficiency to 92%. Each 1% increase in overall electric drive system efficiency, with other conditions unchanged, translates into an estimated 2% increase in EV range. Powerful system integrations deliver industry-leading power-to-weight ratio of 2.5 kW/kg, ensuring less whole-car weight while creating a more spacious and quieter cabin.
- X-HP Smart Thermal Management System: X-HP offers an intelligent, systematic energy-efficient solution for temperatures from -30℃ to 55℃, ensuring range and charging capacity under all weather conditions. In cold conditions, it increases range by 15%; it improves battery cooling performance by 100%, leading to a 90% increase in charging power.
- Powerful Fast-Charging Network: Consisting of 7kW and 11kW home charging piles, 20kW DC fast-charging piles, S2 180kW DC supercharging piles and S4 480kW DC superfast charging piles across China, XPENG’s charging network continues to expand. In 2023, approximately 500 new S4-enabled XPENG superfast charging stations will become operational.
Advanced Manufacturing Capabilities
- Front and Rear Integrated Aluminum Die Casting Technology: One of its kind in mass production models in China, enables more uniform fabrication of the car body, bringing more stable control and a better driving performance. It also improves torsional rigidity by 83% compared to a traditional car body, enhancing body safety, while at the same time reducing body weight by 17% versus traditional bodies, further boosting EV range.
- CIB (Cell Integrated Body) Technology: Battery pack integrated in the car body optimizes cabin design with added vertical space, increases battery safety and enhances overall driving performance by improving center of gravity. With an 80-ton side collision resistance design and a IP68 waterproof & dustproof design, the CIB battery pack meets the highest safety standards in three main markets: China, North America and Europe.
- Chassis Platform: Compatible with multiple types of suspension systems, providing superior mechanical quality and excellent handling performance.
- Smart Manufacturing System: This system will be built out by 2025, including the Zhaoqing Plant, Guangzhou Base and several future projects. All manufacturing facilities will integrate SEPA2.0 through technology upgrades.
About XPENG
XPENG is a leading Chinese Smart EV company that designs, develops, manufactures, and markets Smart EVs that appeal to the large and growing base of technology-savvy middle-class consumers. Its mission is to drive Smart EV transformation with technology, shaping the mobility experience of the future. In order to optimize its customers’ mobility experience, XPENG develops in-house its full-stack advanced driver-assistance system technology and in-car intelligent operating system, as well as core vehicle systems including the powertrain and the electrical/electronic architecture. XPENG is headquartered in Guangzhou, China, with main offices in Beijing, Shanghai, Silicon Valley, San Diego and Amsterdam. The Company’s Smart EVs are mainly manufactured at its plants in Zhaoqing and Guangzhou, Guangdong province. For more information, please visit https://heyXPENG.com.
Safe Harbor Statement
This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar statements. Statements that are not historical facts, including statements about XPENG’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: XPENG’s goals and strategies; XPENG’s expansion plans; XPENG’s future business development, financial condition and results of operations; the trends in, and size of, China’s EV market; XPENG’s expectations regarding demand for, and market acceptance of, its products and services; XPENG’s expectations regarding its relationships with customers, contract manufacturers, suppliers, third-party service providers, strategic partners and other stakeholders; general economic and business conditions; and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in XPENG’s filings with the SEC. All information provided in this press release is as of the date of this press release, and XPENG does not undertake any obligation to update any forward-looking statement, except as required under applicable law.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230416005077/en/
Contact information
For Investor Enquiries:
IR Department
XPeng Inc.
Email: ir@xiaopeng.com
Jenny Cai
The Piacente Group
Tel: +1 212 481 2050 / +86 10 6508 0677
Email: xpeng@tpg-ir.com
For Media Enquiries:
PR Department
XPeng Inc.
Email: pr@xiaopeng.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Coolbrook Secures Business Finland Funding to Accelerate Electrification for the Global Steel Industry29.6.2026 11:00:00 EEST | Press release
Coolbrook, a transformational technology company dedicated to decarbonising heavy industry and industrial processes, has been awarded research and development funding by Business Finland to accelerate the decarbonisation of steel production. The grant supports Coolbrook’s participation in the FutSteel project, a core component of the Sustainable World through Steels ecosystem led by SSAB. Within the broader FutSteel project, Coolbrook’s project scope amounts to €5 million, of which €2.5 million is covered by grant funding awarded to Coolbrook. The funding will enable Coolbrook to further accelerate and develop its next-generation RotoDynamic Heater™ (RDH™) technology, specifically tailored for high-temperature steel industry applications. The project focuses on integrating RDH™ technology into critical stages of the steel production chain, including blast furnace processes, electrified reheating, hot-stove air pre-heating, hybrid-heating concepts, decarbonised Direct Reduced Iron (DRI)
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 10:19:00 EEST | Press release
Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patients with unmet needs.” Pembrolizumab is a humanized monoclonal antibody that acts as an immune checkpoint inhibitor by targeting and blocking the programmed cell death protein 1 (PD-1) receptor on T cells. It is used to treat vari
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 10:00:00 EEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 10:00:00 EEST | Press release
Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European Medicines Agency (EMA) for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/DDC inhibitor-based treatment regimens. CHMP recommendation is based on data from the Phase 3 RISE-PD trial, which compared Hopledo® with immediate release levodopa/carbidopa (LD/CD) formulation in patients with Parkinson’s disease and moderate to severe motor fluctuations. In the study, Hopledo® demonstrated a significant increase in Good ON time over immediate release LD/CD with fewer daily doses and a comparable safety profile1. Hopledo® is a first-in-class, oral, modified-release formulation of LD/CD designed for the treatment of fluctuations of Parkinson’s diseas
Enhertu ® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 09:30:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across three phase 2 trials, including DESTINY-PanTumor02, DESTINY-Lung01 and DESTINY-CRC02. In DESTINY-PanTumor02, Enhertu demonstrated a confirmed objective response rate (ORR) of 52.3% (95% confidence interval [CI]: 42.6-6
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
